Genmab — Januar 2019
-
-
ADC Therapeutics Doses First Patient in Phase Ib Clinical Trial of ADCT-301 in Patients with Advanced Solid Tumors https://globenewswire.com/news-release/2019/01/04/1680461/0/en/ADC-Therapeutics-Doses-First-Patient-in-Phase-Ib-Clinical-Trial-of-ADCT-301-in-Patients-with-Advanced-Solid-Tumors.html
-
-
Jefferies includes Genmab on 2019 list of favorites, not sure if they have a new target https://theworldnews.net/fr-news/biotechs-les-valeurs-europeennes-preferees-de-jefferies (in French)
-
Jo og lidt vanskeligt, at forstå, at Genmab ikke benyttede optionen til at co-develop på ADCT-301. Eneste minus er vist toksinet, som jeg husker ikke er det bedste (mht bivirkninger). Men stoffet har vist sig ADCETRIS overlegent - et stof fra SGEN, der er tæt på blogbuster status.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
